Cargando…

Liver Transplantation for Pediatric Liver Cancer

Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavo...

Descripción completa

Detalles Bibliográficos
Autores principales: Sindhi, Rakesh, Rohan, Vinayak, Bukowinski, Andrew, Tadros, Sameh, de Ville de Goyet, Jean, Rapkin, Louis, Ranganathan, Sarangarajan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140094/
https://www.ncbi.nlm.nih.gov/pubmed/32204368
http://dx.doi.org/10.3390/cancers12030720
_version_ 1783518918508281856
author Sindhi, Rakesh
Rohan, Vinayak
Bukowinski, Andrew
Tadros, Sameh
de Ville de Goyet, Jean
Rapkin, Louis
Ranganathan, Sarangarajan
author_facet Sindhi, Rakesh
Rohan, Vinayak
Bukowinski, Andrew
Tadros, Sameh
de Ville de Goyet, Jean
Rapkin, Louis
Ranganathan, Sarangarajan
author_sort Sindhi, Rakesh
collection PubMed
description Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series.
format Online
Article
Text
id pubmed-7140094
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-71400942020-04-13 Liver Transplantation for Pediatric Liver Cancer Sindhi, Rakesh Rohan, Vinayak Bukowinski, Andrew Tadros, Sameh de Ville de Goyet, Jean Rapkin, Louis Ranganathan, Sarangarajan Cancers (Basel) Review Unresectable hepatocellular carcinoma (HCC) was first removed successfully with total hepatectomy and liver transplantation (LT) in a child over five decades ago. Since then, children with unresectable liver cancer have benefitted greatly from LT and a confluence of several equally important endeavors. Regional and trans-continental collaborations have accelerated the development and standardization of chemotherapy regimens, which provide disease control to enable LT, and also serve as a test of unresectability. In the process, tumor histology, imaging protocols, and tumor staging have also matured to better assess response and LT candidacy. Significant trends include a steady increase in the incidence of and use of LT for hepatoblastoma, and a significant improvement in survival after LT for HCC with each decade. Although LT is curative for most unresectable primary liver sarcomas, such as embryonal sarcoma, the malignant rhabdoid tumor appears relapse-prone despite chemotherapy and LT. Pediatric liver tumors remain rare, and diagnostic uncertainty in some settings can potentially delay treatment or lead to the selection of less effective chemotherapy. We review the current knowledge relevant to diagnosis, LT candidacy, and post-transplant outcomes for these tumors, emphasizing recent observations made from large registries or larger series. MDPI 2020-03-19 /pmc/articles/PMC7140094/ /pubmed/32204368 http://dx.doi.org/10.3390/cancers12030720 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Sindhi, Rakesh
Rohan, Vinayak
Bukowinski, Andrew
Tadros, Sameh
de Ville de Goyet, Jean
Rapkin, Louis
Ranganathan, Sarangarajan
Liver Transplantation for Pediatric Liver Cancer
title Liver Transplantation for Pediatric Liver Cancer
title_full Liver Transplantation for Pediatric Liver Cancer
title_fullStr Liver Transplantation for Pediatric Liver Cancer
title_full_unstemmed Liver Transplantation for Pediatric Liver Cancer
title_short Liver Transplantation for Pediatric Liver Cancer
title_sort liver transplantation for pediatric liver cancer
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7140094/
https://www.ncbi.nlm.nih.gov/pubmed/32204368
http://dx.doi.org/10.3390/cancers12030720
work_keys_str_mv AT sindhirakesh livertransplantationforpediatriclivercancer
AT rohanvinayak livertransplantationforpediatriclivercancer
AT bukowinskiandrew livertransplantationforpediatriclivercancer
AT tadrossameh livertransplantationforpediatriclivercancer
AT devilledegoyetjean livertransplantationforpediatriclivercancer
AT rapkinlouis livertransplantationforpediatriclivercancer
AT ranganathansarangarajan livertransplantationforpediatriclivercancer